OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Instagram Outage Disrupts Thousands of U.S. Users 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
NEW YORK, Jan. 25, 2017 -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of Endologix Inc. (Nasdaq:ELGX) (“Endologix” or the “Company”) securities during the period between August 2, 2016 through November 16, 2016, inclusive (the “Class Period”).
Investors who have incurred losses in Endologix, Inc, shares are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may also review the filed complaint and obtain additional information concerning the action on our website, www.whafh.com.
If you purchased shares of Endologix Inc. within the class period and would like to become involved in assisting the litigation process, you may, no later than March 6, 2017, request that the Court appoint you lead plaintiff of the proposed class.
The filed Complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Endologix did not have the necessary clinical data for FDA premarket approval of its Nellix® EndoVascular Aneurysm Sealing System; and (2) consequently, the Company’s public statements were materially false and misleading at all relevant times.
On November 16, 2016, Endologix revealed that the FDA requested the Company to provide them with follow up data for two years for patients enrolled in the EVAS-FORWARD-IDE study to assess Nellix. Following this news, Endologix stock dropped $2.02 per share or over 20% to close at $7.82 per share on November 16, 2016.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein Adler Freeman & Herz LLP by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.
Follow the firm and learn about newly filed cases on Twitter and Facebook.
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
Contact: Wolf Haldenstein Adler Freeman & Herz LLP Kevin Cooper, Esq. Gregory Stone, Director of Case and Financial Analysis Email: [email protected], [email protected] or [email protected] Tel: (800) 575-0735 or (212) 545-4708
